Human TRAILR1/TNFRSF10A Antibody AF347 from R&D Systems, a Bio-Techne Brand

Product Specs
ItemHuman TRAILR1/TNFRSF10A Antibody
CompanyR&D Systems, a Bio-Techne Brand
Price $479.00Supplier Page View Company Product Page
Catalog NumberAF347
ApplicationsBioassay,Flow Cytometry,Immunohistochemistry,Immunoprecipitation,Western Blot,Immunohistochemistry-Paraffin,Immunohistochemistry-Frozen,Neutralization,Immunocytochemistry
ReactivityHuman
Conjugate/TagUnconjugated
HostGoat
FormatLyophilized from a 0.2 µm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS
Quantity100 ug (also 25 ug)
TargetTRAILR1/TNFRSF10A
IsotypeIgG
ClonalityPolyclonal
ImmunogenS. frugiperda insect ovarian cell line Sf 21-derived recombinant human TRAIL R1/TNFRSF10A, Ala24-Asn239, Accession # AAC51226
ConcentrationLYOPH
PurityAntigen Affinity-purified
Antibody TypePrimary Antibodies
StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution
NCBI Full Gene NameTNF receptor superfamily member 10a
NCBI Gene AliasesAPO2, CD261, DR4, TRAILR-1, TRAILR1

Specifications/Features

Available conjugates: Unconjugated

Add to Compare List

R&D Systems, a Bio-Techne Brand

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

Company Profile

Website: http://www.rndsystems.com

(1) Activation of the integrated stress response and loss of cFLIPL under glutamine limitation induce IL-8 gene expression and secretion in glutamine-dependent tumor cellsCell Death DiscovJuly 19, 2025Rocío Mora-Molina, F. Javier Fernández-Farrán, Abelardo López-Rivas, Carmen PalaciosUSA). The anti-ATF4 antibody (10835-1-AP) was purchased from Proteintech (IL, USA). Anti-TRAIL-R1 (AF347), anti-TRAIL-R2/DR5 (AF631) and recombinant TRAIL-R2-Fc chimeric protein (631-T2) were obtained from

(2) Limiting glutamine utilization activates a GCN2/TRAIL-R2/Caspase-8 apoptotic pathway in glutamine-addicted tumor cellsCell death & diseaseOctober 27, 2022Yerbes R, Mora-Molina R, Fernández-Farrán FJ, Hiraldo L, López-Rivas A, Palacios C.(SC-374609) and anti-ATF4 (D4B8) antibodies were from Santa Cruz Biotechnology (CA, USA). Anti-TRAIL-R1 (AF347), anti-TRAIL-R2 (AF631) and Recombinant TRAIL-R2-Fc chimeric protein (631-T2) were from R&D Systems

(3) CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicityNature communicationsMarch 25, 2022Joung J, Kirchgatterer PC, Singh A, Cho JH, Nety SP, Larson RC, Macrae RK, Deasy R, Tseng YY, Maus MV, et al.(Novus Biologicals NB100-56618, 1:200), MICB (R&D Systems MAB1599-100, 1:500), TNFRSF10A (R&D Systems AF347, 1:200), PVR (R&D Systems MAB25301, 1:500), MICA (R&D Systems MAB1300-100, 1:500), HMGB1 (Abcam ab18256,

(4) Cytotoxic Efficacy and Resistance Mechanism of a TRAIL and VEGFA-Peptide Fusion Protein in Colorectal Cancer ModelsInternational journal of molecular sciencesMarch 19, 2021Kopczynski M, Statkiewicz M, Cybulska M, Kuklinska U, Unrug-Bielawska K, Sandowska-Markiewicz Z, Grochowska A, Gajewska M, Kulecka M, Ostrowski J, et al.solution II (0.01% w/v saponin and 0.2% gelatin in PBS). The following antibodies were used: TNFRSF10A (AF347, R&D Systems, Minneapolis, MN, USA), TNFRSF10B (AF631, R&D Systems, Minneapolis, MN, USA), TNFRSF10C

(5) Designed ferritin nanocages displaying trimeric TRAIL and tumor-targeting peptides confer superior anti-tumor efficacyScientific reportsNovember 17, 2020Yoo JD, Bae SM, Seo J, Jeon IS, Vadevoo SMP, Kim SY, Kim IS, Lee B, Kim S.cell culture dishes and cultured for 24 h. For blocking TRAIL-mediated interaction, anti-DR4 antibody (AF347, R&D systems, Minneapolis, MN, USA; 200 ng/mL) or anti-DR5 antibody (CDM234, Cellsciences, Newburyport,

(6) TRAIL-induced variation of cell signaling states provides nonheritable resistance to apoptosisLife science allianceDecember 1, 2019Baskar R, Fienberg HG, Khair Z, Favaro P, Kimmey S, Green DR, Nolan GP, Plevritis S, Bendall SC.10 min. Fixed cells were stained with 4 μg/ml of TRAIL receptor 1 primary antibody (Catalog number AF347 from R&D systems) and anti-goat secondary antibody conjugated to Alexa 488 (ab150129; Abcam) for 30

(7) PIM kinases mediate resistance of glioblastoma cells to TRAIL by a p62/SQSTM1-dependent mechanismCell death & diseaseJanuary 18, 2019Serrano-Saenz S, Palacios C, Delgado-Bellido D, López-Jiménez L, Garcia-Diaz A, Soto-Serrano Y, Casal JI, Bartolomé RA, Fernández-Luna JL, López-Rivas A, et al.

(8) Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcomaCancer medicineSeptember 1, 2017Liapis V, Zysk A, DeNichilo M, Zinonos I, Hay S, Panagopoulos V, Shoubridge A, Difelice C, Ponomarev V, Ingman W, et al.

(9) Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cellsCell death & diseaseAugust 31, 2017Shlyakhtina Y, Pavet V, Gronemeyer H.(Cambridge, MA, USA) (anti-EEA1 cat. AB2900). Antibodies for immunoprecipitation of DR5 (AF631), DR4 (AF347), DcR2 (AF633), TRAF2 (AF3277) and normal goat IgG (AB-108-C) were purchased from R&D Systems (Minneapolis,

(10) Downregulation of DcR3 sensitizes hepatocellular carcinoma cells to TRAIL-induced apoptosisOncoTargets and therapyJanuary 1, 2017Liang C, Xu Y, Li G, Zhao T, Xia F, Li G, Zhang D, Wu J.

(11) Doxorubicin overcomes resistance to drozitumab by antagonizing Inhibitor of Apoptosis Proteins (IAPs)Anticancer researchDecember 1, 2014Zinonos I, Labrinidis A, Liapis V, Hay S, Panagopoulos V, Denichilo M, Ponomarev V, Ingman W, Atkins GJ, Findlay DM, et al.

(12) TRAIL induces apoptosis in oral squamous carcinoma cells--a crosstalk with oncogenic Ras regulated cell surface expression of death receptor 5OncotargetFebruary 1, 2013Chen JJ, Mikelis CM, Zhang Y, Gutkind JS, Zhang B.and streptomycin. Recombinant human TRAIL (rhTRAIL), monoclonal antibodies specific to TRAIL death receptor-4 (AF347) and -5 (MAB6312) and their phycoerythrin (PE)conjugated forms were purchased from R&D Systems (Minneapolis,

(13) Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cellsOncotargetAugust 1, 2012Chen JJ, Shen HC, Rivera Rosado LA, Zhang Y, Di X, Zhang B.anti-DR antibody for 1 hour at room temperature. Antibodies for immunohistochemistry were: anti-DR4 (#AF347, R&D Systems), anti-DR5 (#ALX-210-743-C200, Enzo Life Sciences) anti-Fas/CD95 (#VP-F702, Vector Lab)

(14) Myricetin sensitizes malignant glioma cells to TRAIL-mediated apoptosis by down-regulation of the short isoform of FLIP and bcl-2Cancer lettersOctober 8, 2009Siegelin MD, Gaiser T, Habel A, Siegelin Y.

(15) Down-regulation of FoxO-dependent c-FLIP expression mediates TRAIL-induced apoptosis in activated hepatic stellate cellsCellular signallingOctober 1, 2009Park SJ, Sohn HY, Yoon J, Park SI.

(16) Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomasClinical cancer research : an official journal of the American Association for Cancer ResearchSeptember 1, 2009Elias A, Siegelin MD, Steinmüller A, von Deimling A, Lass U, Korn B, Mueller W.

(17) Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathwayBiochemical pharmacologyApril 15, 2009Park SJ, Kim MJ, Kim HB, Sohn HY, Bae JH, Kang CD, Kim SH.

(18) Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cellsInternational journal of oncologyAugust 1, 2008Festuccia C, Gravina GL, D'Alessandro AM, Millimaggi D, Di Rocco C, Dolo V, Ricevuto E, Vicentini C, Bologna M.

(19) TRAIL recombinant adenovirus triggers robust apoptosis in multidrug-resistant HL-60/Vinc cells preferentially through death receptor DR5Human gene therapyJuly 1, 2008Wu CH, Kao CH, Safa AR.

(20) Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulationCancer researchJanuary 1, 2008Kim EH, Yoon MJ, Kim SU, Kwon TK, Sohn S, Choi KS.